‘The next phase will be to develop a way to stop the tumors from developing at an early on stage so that they do not have to be surgically removed.’.. Absence of Shp-2 enzyme near cartilage cells can result in multiple benign cartilage tumors in mice These tumors can become malignant in individuals Rhode Island Hospital researchers have found that the lack of the Shp-2 enzyme near specialized cartilage cells can result in the development of multiple benign cartilage tumors in mice, a model that recapitulates the rare human tumor syndrome metachondromatosis. Shp2 is an enzyme in the cell that regulates the activity of various other proteins and signaling pathways.‘Aerie is a head in the field of ophthalmology with their portfolio of innovative glaucoma products, and we feel privileged to donate to that success.’ ‘Even though glaucoma is certainly a progressive disease, there’s not been a medication with a new mechanism of action authorized in the glaucoma field since the mid-nineties,’ said Dr. Mehra. ‘Patients often need several drugs to regulate their disease, and physicians have limited choices with these old mechanisms. We think that AR-12286’s new MOA, strong efficacy, superb tolerability, as soon as daily dosing can provide real value to patients at risk of losing their vision.’ In addition to Aerie’s lead plan, the business is pursuing several pipeline applications including also, AR-13324, the to begin a novel glaucoma medication class discovered at Aerie with a distinctive dual-mechanism.